{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053894","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.956546+00:00","generated_at":"2026-06-09T21:58:02.655971+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma","bullets":["Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.","HSV-1 seropositive patients had median OS 14.2 months vs 7.8 months for seronegative; seroconversion linked to improved survival.","Treatment well tolerated with no dose-limiting toxicity; increased immune cell infiltration and T-cell repertoire diversity observed.","Arm C will evaluate up to six injections of CAN-3110, supported by Break Through Cancer foundation.","Publication in Nature titled 'Clinical trial links oncolytic immunoactivation to survival in glioblastoma'."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053894","json":"https://secwatch.observer/filing/0000950170-23-053894.json","markdown":"https://secwatch.observer/filing/0000950170-23-053894.md","text":"https://secwatch.observer/filing/0000950170-23-053894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/0000950170-23-053894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023053894/cadl-20231018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:58:02.655971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}